NeoImmuneTech Announces First Patient Dosed in Phase II Study of NT-I7 (efineptakin alfa) with PD-L1 Checkpoint Inhibitor in High-Risk Skin Cancers

NeoImmuneTech, Inc. announced that the first patient has been dosed in the Phase IIa portion of a study evaluating NT-I7, a novel long-acting human interleukin-7, in combination with the PD-L1 targeting drug atezolizumab, in patients with advanced high-risk skin cancers including melanoma, merkel cell carcinoma, and cutaneous squamous cell carcinoma.